BRPI0918526B1 - Forma cristalina polimórfica anidra de acil sulfonamidas, seu processo de preparação, uso e composição farmacêutica que a compreende - Google Patents

Forma cristalina polimórfica anidra de acil sulfonamidas, seu processo de preparação, uso e composição farmacêutica que a compreende Download PDF

Info

Publication number
BRPI0918526B1
BRPI0918526B1 BRPI0918526-7A BRPI0918526A BRPI0918526B1 BR PI0918526 B1 BRPI0918526 B1 BR PI0918526B1 BR PI0918526 A BRPI0918526 A BR PI0918526A BR PI0918526 B1 BRPI0918526 B1 BR PI0918526B1
Authority
BR
Brazil
Prior art keywords
compound
acid
hiv
polymorphic
crystalline form
Prior art date
Application number
BRPI0918526-7A
Other languages
English (en)
Portuguese (pt)
Inventor
James Prentice Davidson
Michael Martin
Fei Pang
Margaret Wong
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to BR122021020474-8A priority Critical patent/BR122021020474B1/pt
Priority to BR122021020475-6A priority patent/BR122021020475B1/pt
Publication of BRPI0918526A2 publication Critical patent/BRPI0918526A2/pt
Publication of BRPI0918526B1 publication Critical patent/BRPI0918526B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0918526-7A 2008-09-09 2009-08-31 Forma cristalina polimórfica anidra de acil sulfonamidas, seu processo de preparação, uso e composição farmacêutica que a compreende BRPI0918526B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122021020474-8A BR122021020474B1 (pt) 2008-09-09 2009-08-31 Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BR122021020475-6A BR122021020475B1 (pt) 2008-09-09 2009-08-31 Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9536408P 2008-09-09 2008-09-09
US61/095,364 2008-09-09
PCT/EP2009/061185 WO2010028968A2 (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides

Publications (2)

Publication Number Publication Date
BRPI0918526A2 BRPI0918526A2 (pt) 2015-12-01
BRPI0918526B1 true BRPI0918526B1 (pt) 2022-02-15

Family

ID=41664548

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0918526-7A BRPI0918526B1 (pt) 2008-09-09 2009-08-31 Forma cristalina polimórfica anidra de acil sulfonamidas, seu processo de preparação, uso e composição farmacêutica que a compreende
BR122021020474-8A BR122021020474B1 (pt) 2008-09-09 2009-08-31 Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BR122021020475-6A BR122021020475B1 (pt) 2008-09-09 2009-08-31 Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122021020474-8A BR122021020474B1 (pt) 2008-09-09 2009-08-31 Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BR122021020475-6A BR122021020475B1 (pt) 2008-09-09 2009-08-31 Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende

Country Status (16)

Country Link
US (1) US8063103B2 (enExample)
EP (1) EP2334638B1 (enExample)
JP (6) JP5989339B2 (enExample)
KR (7) KR20180001582A (enExample)
CN (1) CN102143943B (enExample)
AU (1) AU2009290988B2 (enExample)
BR (3) BRPI0918526B1 (enExample)
CA (5) CA3059552C (enExample)
EA (1) EA019340B1 (enExample)
ES (1) ES2706875T3 (enExample)
IL (4) IL299322B2 (enExample)
MX (1) MX2011002319A (enExample)
PL (1) PL2334638T3 (enExample)
TR (1) TR201818979T4 (enExample)
UA (1) UA107561C2 (enExample)
WO (1) WO2010028968A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644156C1 (ru) 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
RU2716257C1 (ru) * 2019-04-30 2020-03-11 Андрей Александрович Иващенко Активный компонент, фармацевтическая композиция и лекарственный препарат для терапии ВИЧ и СПИДа
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098841C (zh) * 1997-01-23 2003-01-15 山之内制药株式会社 新颖的酰胺衍生物及其医药组合物
US7625949B2 (en) * 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
ES2333802T3 (es) * 2004-04-23 2010-03-01 F. Hoffmann-La Roche Ag Inhibidores no nucleicos de transcriptasa inversa.
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
AU2006238933B2 (en) * 2005-04-28 2011-12-01 Pfizer Limited Amino acid derivatives
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
CN101291905A (zh) * 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
CA2716082A1 (en) * 2008-03-04 2009-02-23 F. Hoffmann-La Roche Ag Process for preparing concentrated aqueous micellar solutions

Also Published As

Publication number Publication date
JP5989339B2 (ja) 2016-09-07
WO2010028968A2 (en) 2010-03-18
BR122021020474B1 (pt) 2022-06-07
CN102143943B (zh) 2014-03-12
EA019340B1 (ru) 2014-02-28
PL2334638T3 (pl) 2019-04-30
TR201818979T4 (tr) 2019-01-21
US20100063154A1 (en) 2010-03-11
CA2949912A1 (en) 2010-03-18
EP2334638A2 (en) 2011-06-22
US8063103B2 (en) 2011-11-22
CA3003213A1 (en) 2010-03-18
JP2016172741A (ja) 2016-09-29
KR20180110237A (ko) 2018-10-08
KR20230113420A (ko) 2023-07-28
IL211353A0 (en) 2011-05-31
CA3003213C (en) 2021-07-20
CA3059552C (en) 2021-03-16
JP2019194229A (ja) 2019-11-07
IL211353A (en) 2016-04-21
CA3059552A1 (en) 2010-03-18
JP2023082131A (ja) 2023-06-13
KR101822319B1 (ko) 2018-01-25
CA3086566C (en) 2025-09-02
KR101678700B1 (ko) 2016-11-22
AU2009290988B2 (en) 2016-01-28
CN102143943A (zh) 2011-08-03
KR102437499B1 (ko) 2022-08-29
KR20110053234A (ko) 2011-05-19
KR20180001582A (ko) 2018-01-04
BR122021020475B1 (pt) 2022-06-07
KR20210108499A (ko) 2021-09-02
AU2009290988A1 (en) 2010-03-18
CA3086566A1 (en) 2010-03-18
CA2949912C (en) 2019-12-03
ES2706875T3 (es) 2019-04-01
MX2011002319A (es) 2011-04-05
IL299322B2 (en) 2024-10-01
IL299322B1 (en) 2024-06-01
KR20160092049A (ko) 2016-08-03
JP2021176894A (ja) 2021-11-11
CA2735192A1 (en) 2010-03-18
JP2012502075A (ja) 2012-01-26
IL264118A (en) 2019-02-28
CA2735192C (en) 2017-02-28
BRPI0918526A2 (pt) 2015-12-01
UA107561C2 (xx) 2015-01-26
JP2018058862A (ja) 2018-04-12
KR102560207B1 (ko) 2023-07-27
JP6450340B2 (ja) 2019-01-09
IL299322A (en) 2023-02-01
WO2010028968A3 (en) 2010-06-10
IL244350A0 (en) 2016-05-01
EP2334638B1 (en) 2018-11-21
EA201100451A1 (ru) 2011-10-31
KR20220120723A (ko) 2022-08-30

Similar Documents

Publication Publication Date Title
JP4627315B2 (ja) 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
JP2023082131A (ja) アシルスルホンアミドの多形体

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.